Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan and 4 Gy TBI conditioning with rapamycin-based graft-versus-host disease prophylaxis for allogeneic stem cell transplantation
2011-001534-42Phase 2Completed
- Sponsor
- Fondazione Centro San Raffaele
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan, fludarabine, sirolimus, antithymocyte immunoglobulin, rituximab and 1 more in hematopoietic malignancies, leukemia, multiple myeloma (MM) and 1 more, sponsored by Fondazione Centro San Raffaele. Primary endpoint: Progression-free survival at 1 year. Started May 2012; status: completed.
02
Drugs
treosulfanfludarabinesirolimusantithymocyte immunoglobulinrituximab
03
Conditions
hematopoietic malignanciesleukemiamultiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on 2011-001534-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001534-42.